Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia

Bibliography

• Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-30
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Nagel RL. Sickle cell disease. Lancet 2004;364:1343-60
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical phenotypes. Blood Rev 2007;21:37-47
   PubMed Web of Science ®Google Scholar
• Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16
   PubMed Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89:1787-92
   PubMed Web of Science ®Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002;8:1383-9
   PubMed Web of Science ®Google Scholar
• McBurney PG, Hanevold CD, Hernandez CM, et al. Risk factors for microalbuminuria in children with sickle cell anemia. J Pediatr Hematol Oncol 2002;24:473-7
   PubMed Web of Science ®Google Scholar
• Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study. Arch Intern Med 2007;167:701-8
   PubMed Web of Science ®Google Scholar
• Ataga KI, Brittain J, Jones SK, et al. Clinical and laboratory Correlates of Albuminuria in Sickle Cell Disease. Annual Meeting of the American Society of Hematology, San Francisco, CA; 2008
   Google Scholar
• Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95
   PubMed Web of Science ®Google Scholar
• Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med 2004;117:665-9
   PubMed Web of Science ®Google Scholar
• Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003;101:1257-61
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006;134:109-15
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94
   PubMed Web of Science ®Google Scholar
• Kato GJ, Hsieh M, Machado RF, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006;81:503-10
   PubMed Web of Science ®Google Scholar
• Lezcano NE, Odo N, Kutlar A, et al. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006;37:1424-6
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11
   PubMed Web of Science ®Google Scholar
• Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 1991;115:614-20
   PubMed Web of Science ®Google Scholar
• De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008;83:19-25
   PubMed Web of Science ®Google Scholar
• Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-9
   PubMed Web of Science ®Google Scholar
• Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 1987;237:500-6
   PubMed Web of Science ®Google Scholar
• Lew VL, Etzion Z, Bookchin RM. Dehydration response of sickle cells to sickling-induced Ca(++) permeabilization. Blood 2002;99:2578-85
   PubMed Web of Science ®Google Scholar
• Lew VL, Hockaday A, Sepulveda MI, et al. Compartmentalization of sickle-cell calcium in endocytic inside-out vesicles. Nature 1985;315:586-9
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003;9:496-500
   PubMed Web of Science ®Google Scholar
• Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003;348:1483-5
   PubMed Web of Science ®Google Scholar
• Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-9
   PubMed Web of Science ®Google Scholar
• van de Poll MC, Hanssen SJ, Berbée M, et al. Elevated plasma arginase-1 does not affect plasma arginine in patients undergoing liver resection. Clin Sci (Lond) 2008;114:231-41
   PubMed Web of Science ®Google Scholar
• Landburg PP, Teerlink T, van Beers EJ, et al. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. Haematologica 2008;93:1410-2
   PubMed Web of Science ®Google Scholar
• Hebbel RP. Auto-oxidation and a membrane-associated ‘Fenton reagent’: a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985;14:129-40
   PubMedGoogle Scholar
• Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003;107:271-8
   PubMed Web of Science ®Google Scholar
• Setty BN, Stuart MJ, Dampier C, et al. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003;362:1450-5
   PubMed Web of Science ®Google Scholar
• Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107:2279-85
   PubMed Web of Science ®Google Scholar
• Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle cell disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110:2166-72
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008;93:20-26
   PubMed Web of Science ®Google Scholar
• Setty BN, Betal SG, Zhang J, Stuart MJ. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Stocker JW, De Franceschi L, McNaughton-Smith GA, et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003;101:2412-8
   PubMed Web of Science ®Google Scholar
• McNaughton-Smith GA, Burns JF, Stocker JW, et al. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem 2008;51:976-82
   PubMed Web of Science ®Google Scholar
• Grizzle TB, Rigdon GC, Stocker JW, et al. “Nonclinical Evaluations of ICA-17043: an Investigational Drug for Treatment of Sickle Cell Disease (SCD).” 45th Annual Meeting of the Society of Toxicology; San Diego, CA; 2006
   Google Scholar
• Stocker JW, Bergman KL, Ridgon GC. “Pharmacokinetics (PK) and Pharmacodynamics (PD) of ICA-17043 (ICA), a Novel Gardos Channel Inhibitor for the Treatment of Sickle Cell Disease, Following Single, Ascending Doses in Healthy, Male Subjects.” American College of Clinical Pharmacology Meeting, Vienna, VA; 2001
   Google Scholar
• Ataga KI, Orringer EP, Styles L, et al. Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 2006;11:1557-64
   Google Scholar
• Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111:3991-7
   PubMed Web of Science ®Google Scholar
• Swerdlow P, Ataga K, Smith W, et al. A 48-week open-label study of senicapoc (ICA-17043), a Gardos channel blocker, in patients with sickle cell disease. Blood 2006;108:685
   PubMed Web of Science ®Google Scholar
• Icagen, Inc. Press Release. Business Wire. April 3, 2007
   Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22
   PubMed Web of Science ®Google Scholar
• Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-6
   PubMed Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44
   PubMed Web of Science ®Google Scholar